CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
rituximabbiological
Likely dose
rituximab 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01554514
NCT01554514Phase 2Completed
CompareCT.gov

Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency

Washington University School of Medicine·interventional·Posted Mar 15, 2012·Updated Aug 17, 2021

In Brief

A Phase 2 clinical trial evaluating rituximab for Thrombotic Thrombocytopenic Purpura. Completed, enrolled 19 participants across 4 sites.

Detailed Summary

Thrombotic thrombocytopenic purpura (TTP) is a disease characterized by small blood clots throughout the body that can damage major organs and cause death. TTP is treated with plasma exchange (also called "plasmapheresis"). Patients who do not respond initially to plasma exchange often are helped by later treatment with rituximab. The purpose of this study is to see whether combining low doses of rituximab with plasma exchange will help patients get better sooner and reduce the chance of getting TTP again.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThrombotic Thrombocytopenic Purpura
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 15, 2012
Enrollment StartAug 1, 2012
Primary CompletionFeb 14, 2020
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 14.3 years ago

Interventions

rituximabbiological

rituximab intravenously 100 mg every week for four doses